Market access does not automatically mean patient access. In order for patients to benefit from innovative medicines and medtech solutions, also clinicians and patient advocacy groups need to understand their value and value for money.
Prof. Dr. Lieven Annemans, well known for his broad HTA expertise and excellent presentation skills, will provide his insights as to what the principles and methods of health economic evaluations and HTA mean for clinicians and patients:
How to talk about value for money to clinicians and patient advocacy groups
How to align the clinical and the health economic view
How to go beyond the QALY to account for what matters to patients
How to deal with evidence gaps: the increasing role of Real World Evidence
Expert faculty member of Health Economics for Non-Health-Economists, How to Optimally Manage HTA Criteria & Processes in Europe and Basics of Health Economics.
Participated in 100s of health economic evaluations globally across a wide spectrum of therapeutic areas.
A unique profile: academic professor, past-president ISPOR, consultant and author of Health economics for non-economists (Pelckmans Pro, 2018)
Much sought-after advisor and educator to health policy makers and the innovative healthcare industry.
Please note that this webinar is only open to managers working in the pharma/biotech/medtech industry.
For your registration to be approved, please enter your COMPANY EMAIL address.
(*) if you cannot attend the webinar, please note that a recorded playback
will be sent to all registrants after the webinar.